FluGen is dedicated to improving public health by developing a vaccine that can prevent disease caused by all forms of the deadly influenza virus. We are fighting a virus that mutates quickly and results in over 200,000 hospitalizations and up to 36,000 deaths each year in the U.S. alone. Worldwide, influenza causes 250,000 to 300,000 deaths every year. Based in Madison, Wisconsin, FluGen is developing RedeeFlu™, an influenza vaccine that is poised to enter human trials. We are committed to forging a new and more effective weapon in the fight against influenza.
FluGen, UW-Madison researchers developing COVID-19 vaccine
David Wahlberg | Wisconsin State Journal Apr 3, 2020 David Marshall, left, research scientist, and Mike Moser, senior scientist, look at cells being grown for studies of an experimental flu vaccine at FluGen, on Madison's West Side. AMBER ARNOLD, STATE JOURNAL...
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus
— Topline data shows first flu vaccine to demonstrate protection against a multi-season mismatched H3N2 strain in a human challenge clinical trial — — Intranasal administration of M2SR well-tolerated in trial — — Protection against influenza challenge correlated with...
FluGen brings in more money to get ready for more studies of its universal flu vaccine
JUDY NEWMAN jdnewman@madison.com Nov 25, 2018 Research scientist David Marshall, left, and senior scientist Mike Moser look at cells being grown for studies of an experimental flu vaccine at FluGen. AMBER ARNOLD, STATE JOURNAL ARCHIVES FluGen is just finishing one...